The PE Ratio as of November 2024 (TTM) for Bicycle Therapeutics plc (BCYC) is -6.24

According to Bicycle Therapeutics plc’s latest financial reports and current stock price. The company's current PE Ratio is -6.24. This represents a change of -99.68% compared to the average of -1925.77 of the last 4 quarters.

Bicycle Therapeutics plc (BCYC) Historical PE Ratio (quarterly & annually)

How has BCYC PE Ratio performed in the past?

The mean historical PE Ratio of Bicycle Therapeutics plc over the last ten years is -9.64. The current -6.24 PE Ratio has changed 6.37% with respect to the historical average. Over the past ten years (40 quarters), BCYC's PE Ratio was at its highest in in the December 2017 quarter at -0.18. The PE Ratio was at its lowest in in the September 2024 quarter at -7682.86.

Bicycle Therapeutics plc (BCYC) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Bicycle Therapeutics plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Bicycle Therapeutics plc (BCYC) Average PE Ratio

How has BCYC PE Ratio performed in the past?

The current PE Ratio of Bicycle Therapeutics plc (BCYC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Bicycle Therapeutics plc (BCYC) PE Ratio vs. Peers

How is BCYC’s PE Ratio compared to its peers?

Bicycle Therapeutics plc’s PE Ratio is greater than IDEAYA Biosciences, Inc. (-15.24), less than AnaptysBio, Inc. (-3.19), less than MeiraGTx Holdings plc (-4.14), greater than Keros Therapeutics, Inc. (-12.93), less than Homology Medicines, Inc. (-0.01), less than Tenaya Therapeutics, Inc. (-1.73), less than IGM Biosciences, Inc. (-4.35), less than Monte Rosa Therapeutics, Inc. (-4.84), greater than Stoke Therapeutics, Inc. (-7.00), greater than Merus N.V. (-14.36), less than Inhibrx Biosciences, Inc. (0.14), greater than immatics biotechnologies GmbH (-12.03), less than Seer, Inc. (-1.56), less than ORIC Pharmaceuticals, Inc. (-6.02), less than Anebulo Pharmaceuticals, Inc. (-5.95), less than Cullinan Oncology, Inc. (-6.18), less than C4 Therapeutics, Inc. (-4.29), less than Adagene Inc. (-4.20), less than Acrivon Therapeutics, Inc. Common Stock (-4.10), less than Mineralys Therapeutics, Inc. (-5.55),

Build a custom stock screener for Bicycle Therapeutics plc (BCYC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bicycle Therapeutics plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Bicycle Therapeutics plc (BCYC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Bicycle Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.